Skip to Content

Molindone Dosage

Medically reviewed on March 7, 2017.

Applies to the following strengths: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 20 mg/mL

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Schizophrenia

Initial Dosing Schedule:
-Recommended dose: 50 to 75 mg orally per day, increasing the dose to 100 mg/day in 3 to 4 days
-Maximum dose: 225 mg/day

Maintenance Dosing Schedule:
-Mild symptomology: 5 to 15 mg orally 3 to 4 times a day
-Moderate symptomology: 10 to 25 mg orally 3 to 4 times a day
-Severe symptomology: Up to 225 mg/day

Comments:
-Patients with severe symptomology may require 225 mg/day.
-Elderly and/or debilitates patients should begin on the lower dosage.

Use: Management of schizophrenia

Usual Pediatric Dose for Schizophrenia

12 to 18 years:
Initial Dosage Schedule:
-Recommended dose: 50 to 75 mg orally per day, increasing the dose to 100 mg/day in 3 to 4 days
-Maximum dose: 225 mg/day

Maintenance Dosing Schedule:
-Mild symptomology: 5 to 15 mg orally 3 to 4 times a day
-Moderate symptomology: 10 to 25 mg orally 3 to 4 times a day
-Severe symptomology: Up to 225 mg/day

Comments:
-Patients with severe symptomology may require 225 mg/day.
-Debilitated patients should begin on the lower dosage.

Use: Management of schizophrenia

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

US BOXED WARNING:
-INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS: This drug has an increased risk of mortality when administered to elderly patients with dementia-related psychosis. Elderly patients with dementia-related psychosis treated with antipsychotic drugs have an increased risk of death. This drug is not approved for use in patients with dementia-related psychosis.

Safety and efficacy have not been established in patients younger than 12 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-See manufacturer product information.

Storage requirements:
-See manufacturer product information.

General:
-Effectiveness was determined in clinical studies with newly hospitalized and chronically hospitalized, acutely ill patients with schizophrenia.
-This drug has not been shown effective in the management of behavioral complications in patients with mental impairment.

Monitoring:
-Complete blood count before and periodically during treatment

Patient advice:
-Warn patients to avoid abrupt discontinuation of this drug.
-Tell patients to immediately report any signs/symptoms of neutropenia/leukopenia, neuroleptic malignant syndrome, or tardive dyskinesia.
-Patients should be advised to report all concurrent prescription and nonprescription medications or herbal products they are taking.
-Inform patients that this drug may cause drowsiness, and they should avoid driving or operating machinery until the full effects of the drug are known.
-Patients should be advised to speak to a healthcare provider if they are pregnant, intend to become pregnant, or are breastfeeding.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide